Older patients with colon cancer less likely to receive chemotherapy after surgery

Mar 16, 2010

Even though older patients with colon cancer are less likely to receive chemotherapy following surgery because of concerns of adverse events, new research indicates that when they do receive this treatment, it is less toxic and of shorter duration than therapy younger patients receive, and older patients experience fewer adverse events, according to a study in the March 17 issue of JAMA, a theme issue on cancer.

Study co-author Robert H. Fletcher, M.D., M.Sc., of Harvard Medical School, Boston, presented the findings of the study at a JAMA media briefing.

Randomized trials have shown reductions in cancer death and recurrence in patients with stage III treated with adjuvant (supplemental [after surgery]) chemotherapy, with clinical trials also showing that surgery and increases survival over surgery alone in selected patients with this stage of colon cancer. But in practice, older patients with stage III colon cancer are much less likely to receive this treatment. "Physicians cite the lack of randomized controlled trials evaluating the effectiveness of adjuvant chemotherapy for patients older than 80 years as well as comorbid [co-existing illnesses] conditions and drug toxicities as the most common reasons for not treating older patients with adjuvant chemotherapy," the authors write.

Katherine L. Kahn, M.D., of RAND Corporation, Santa Monica, Calif., and colleagues analyzed the use of adjuvant chemotherapy and adverse events by age, through medical records and surveys, in a multiregional group of 675 patients diagnosed with stage III colon cancer from 2003 through 2005, who underwent surgical resection (removal of part of the colon). The patients, who were followed up for as long as 15 months following their diagnosis, were from five regions (Alabama, Iowa, Los Angeles County, northern California, and North Carolina), five integrated health care delivery systems, and 15 Veterans Affairs hospitals.

The researchers found that overall, 513 of 675 patients with stage III colon cancer (75 percent) received any adjuvant chemotherapy. Of the 202 patients 75 years and older, 101 (50 percent) received supplemental chemotherapy compared with 87 percent of younger patients. Patients aged 65 years and older were more likely than younger patients to discontinue chemotherapy at all follow-up times. For example, by 150 days, 40 percent of patients at least 65 years old had discontinued chemotherapy, compared to 25 percent of younger patients. Among patients receiving adjuvant chemotherapy, adjusted rates of late clinical adverse events were lower for patients 75 years and older vs. for younger patients.

Regarding adverse events, 24 percent of patients had at least 1 adverse event (defined as 31 days after resection and 15 months after diagnosis). These events occurred in more than twice as many patients receiving vs. not receiving adjuvant chemotherapy. The average number of unique adverse events was also higher for adjuvant chemotherapy users vs. nonusers.

"Strategies to help clinicians uncertain about the safety of adjuvant chemotherapy for older patients with comorbidity could increase the likelihood that evidence-based chemotherapy benefits are realized in population-based settings. Using decision support tools built on published trials and population-based analyses such as these can help clinicians predict effectiveness of , even for patients with comorbid conditions and advanced age," the authors write.

"Systematic monitoring of symptoms and signs among users, combined with interventions to evaluate and treat these clues, could help clinicians support patients in meeting evidence-based treatment dosage and duration goals. Clinicians who identify symptoms and signs early and take steps to avoid serious adverse outcomes may enable their patients to complete recommended treatment courses while also improving quality of life."

Explore further: Chronic inflammation linked to 'high-grade' prostate cancer

More information: JAMA. 2010;303[11]:1037-1045.

add to favorites email to friend print save as pdf

Related Stories

Docetaxel given after doxorubicin reduces recurrence

Jan 08, 2008

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the Na ...

Tablet is better all round for cancer patients

Oct 08, 2007

A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

Gene signature may improve colon cancer treatment

Feb 26, 2010

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

Recommended for you

Unraveling the 'black ribbon' around lung cancer

Apr 17, 2014

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments : 0

More news stories

Filipino tests negative for Middle East virus

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

Study says we're over the hill at 24

(Medical Xpress)—It's a hard pill to swallow, but if you're over 24 years of age you've already reached your peak in terms of your cognitive motor performance, according to a new Simon Fraser University study.

NASA's space station Robonaut finally getting legs

Robonaut, the first out-of-this-world humanoid, is finally getting its space legs. For three years, Robonaut has had to manage from the waist up. This new pair of legs means the experimental robot—now stuck ...

Ex-Apple chief plans mobile phone for India

Former Apple chief executive John Sculley, whose marketing skills helped bring the personal computer to desktops worldwide, says he plans to launch a mobile phone in India to exploit its still largely untapped ...

Egypt archaeologists find ancient writer's tomb

Egypt's minister of antiquities says a team of Spanish archaeologists has discovered two tombs in the southern part of the country, one of them belonging to a writer and containing a trove of artifacts including reed pens ...

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.